HealiosHEALIOS K.K.4593東証グロース医薬品FY ending Dec 2023, consolidated, IFRS
Revenue changed +34.4% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | -20.5% | —× | — |
| 2022 | — | —× | -26.5% | —× | — |
| 2023 | — | —× | -25.3% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 |
|---|---|---|---|
| Revenue | 41 | 90 | 121 |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| SG&A | — | — | — |
| Operating income | — | — | — |
| Pretax income | -4,462 | -5,330 | -3,626 |
| Income tax | — | — | — |
| Net income attributable to owners | -4,910 | -5,169 | -3,823 |
| Operating margin | — | — | — |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 |
|---|---|---|---|
| Cash and equivalents | ¥15.1B | ¥7.25B | ¥6.72B |
| Total assets | ¥24B | ¥15B | ¥15.2B |
| Net assets | — | — | ¥3.87B |
EDINET (FSA Japan)
有価証券報告書－第15期(2025/01/01－2025/12/31)
Extracted from XBRL: 10 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.